| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Attovia Therapeutics, Inc. Common Stock's insiders have accumulated 1,558,386 shares worth roughly $26.3M on balance. In the past 30 days, 3 insiders bought and 2 sold. Recent activity has leaned to the buy side.
The largest recent buyer is WALSH COLIN (Director).
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 2.04M | $40.56M | +479.2K | |
| 10% | 782.9K | $15.55M | +600.0K | |
| 10% | 0 | - | +479.2K |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Redmile Group, LLC | 10% Owner | Buy | 600,000 | $17.00 | $10,200,000.00 | +38.3% | |
| Aug 6, 2026 | Walsh Colin | Director | Buy | 585,000 | $17.58 | $10,285,000.00 | +23.2% | |
| Aug 6, 2026 | Goldman Sachs Group Inc58 | Former 10% Owner | Buy | 585,000 | $17.58 | $10,285,000.00 | +23.2% | |
| Aug 5, 2026 | Goldman Sachs Group Inc58 | Former 10% Owner | Sell | 105,807 | $21.28 | $2,251,657.70 | -6.3% | |
| Aug 5, 2026 | Walsh Colin | Director | Sell | 105,807 | $21.28 | $2,251,657.70 | -6.3% |